Philip Morris International Inc.Philip Morris International Inc. (PMI) is the world's leading international tobacco company, with six of the world's top 15 international brands and products sold in more than 180 markets. In addition to the manufacture and sale of cigarettes, including Marlboro, the number one global cigarette brand, and other tobacco products, PMI is engaged in the development and commercialization of Reduced-Risk Products ("RRPs"). RRPs is the term PMI uses to refer to products with the potential to reduce individual risk and population harm in comparison to smoking cigarettes. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and industry-leading scientific substantiation, PMI aims to provide an RRP portfolio that meets a broad spectrum of adult smoker preferences and rigorous regulatory requirements. For more information, see www.pmi.com and www.pmiscience.com.
Philip Morris International Inc. (NYSE/Euronext Paris: PM) today releases the first Reduced-Risk Product (RRP) Scientific Update, a regular publication on its research efforts to develop and assess a range of potentially reduced-risk alternatives to cigarettes. The report is available at http://www.pmi.com/eng/media_center/press_releases/Documents/PMI%20Scientific%20Update%20Sept%202016.pdf. The Update is meant to provide scientists, regulators and others a summary of PMI's product development and assessment approach as well an overview of the latest studies, key peer-reviewed publications and presentations at scientific conferences. It is an important complement to PMI's ongoing efforts to share its latest science, which include a dedicated website ( www.pmiscience.com). Prof. Manuel Peitsch, PMI's Chief Scientific Officer, explains: "We are making significant efforts to develop and scientifically assess innovative products that generate a vapor in which harmful chemicals found in cigarette smoke are significantly reduced or eliminated while the taste, sensory experience and ritual characteristics of smoking are preserved as much as possible. Along with many public health experts, we believe innovative products backed up by solid science can play an important role to reduce the harm of smoking. Sharing our methodologies and findings allows feedback and review from external experts and regulators and can encourage further research in the field." PMI's extensive research is inspired by the well-recognized practices of the pharmaceutical industry and in line with guidance of the U.S. FDA for Modified-Risk Tobacco Products (MRTPs). The Company today employs over 300 world-class scientists who conduct rigorous research, including laboratory and clinical studies, as well as ground-breaking systems toxicology. The assessment program also includes studies on actual product use and correct understanding of product communications, as well as post-market research. Michele Cattoni, PMI's VP Technology and Operations, further elaborates on the Company's efforts: "Technological innovation is transforming our industry with a wide range of noncombustible nicotine products that have the potential to represent significantly reduced-risk alternatives compared to smoking. PMI has been, and will continue to be, a driving force in this transformation. Our ambition is that ultimately reduced-risk alternatives replace cigarettes to the benefit of smokers, society and our company." ###